secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K/A
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001116463-25-000008
Event type: m_and_a
Sentiment:  negative
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition
--------------------------------------------------------------------------------

- Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
- Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.
- Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.
- Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.
- Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/0001116463-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/osur-20241219.htm
  HTML page:      https://secwatch.observer/filing/0001116463-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer